SYFOVRE (Pegcetacoplan) Injection

SYFOVRE (pegcetacoplan), from Apellis Pharmaceuticals, is indicated for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Pegcetacoplan is a complement inhibitor that targets complement protein C3, blocking the complement cascade implicated in the progressive retinal cell damage of geographic atrophy — the first therapy shown to slow the growth of GA lesions.

• Risk of endophthalmitis and retinal detachment associated with intravitreal injections — patients should report any signs of infection promptly.
• Neovascular (“wet”) AMD may develop in patients treated with SYFOVRE; regular monitoring is required.
• Intraocular inflammation and increased intraocular pressure have been reported.
• Must be administered by a qualified ophthalmologist under sterile conditions.

What documents are required to import SYFOVRE to India?

SYFOVRE may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered ophthalmologist/retina specialist
• Diagnostic report confirming geographic atrophy secondary to AMD
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is SYFOVRE available in India?

SYFOVRE is not commercially marketed in India. It can be legally accessed through the Named Patient Program (NPP).

Indian Pharma Network (IPN) can source SYFOVRE from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions, including cold-chain-compliant logistics.

For SYFOVRE cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• United States: Approved by the FDA — February 2023.

What is SYFOVRE used for?

SYFOVRE treats geographic atrophy secondary to age-related macular degeneration, slowing lesion growth.

Who manufactures SYFOVRE?

SYFOVRE is developed by Apellis Pharmaceuticals.

How is SYFOVRE administered?

By intravitreal injection, administered by an ophthalmologist, typically once every 25-60 days.

How much does SYFOVRE cost in India?

Cost depends on treatment frequency and sourcing logistics — share your prescription with IPN for a quote.